Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3951
iShares MSCI Canada ETF
EWC
$6.51B
| $383K | ﹤0.01% |
7,099
-73,810
| -91% | -$3.82M |
|
3952
Flotek Industries
FTK
$1.35B
| $383K | ﹤0.01% |
22,204
+1,351
| +6% | +$21.4K |
|
3953
Lifecore Biomedical
LFCR
$181M
| $382K | ﹤0.01% |
46,696
+6,124
| +15% | +$45.3K |
|
3954
Global Water Resources
GWRS
$219M
| $382K | ﹤0.01% |
45,186
+1,784
| +4% | +$16.8K |
|
3955
Barclays
BCS
$94.4B
| $382K | ﹤0.01% |
15,000
+14,977
| +65,117% | +$332K |
|
|
TBI
3956
Trueblue
TBI
$302M
| $382K | ﹤0.01% |
83,882
+4,245
| +5% | +$21.8K |
|
3957
ProKidney
PROK
$304M
| $381K | ﹤0.01% |
170,001
+170,000
| +17,000,000% | +$447K |
|
3958
GoPro
GPRO
$106M
| $380K | ﹤0.01% |
269,766
+149,792
| +125% | +$272K |
|
3959
Pulse Biosciences
PLSE
$3.09B
| $380K | ﹤0.01% |
27,652
+2,164
| +8% | +$33.7K |
|
|
STLN
3960
Starling Oncology, Inc. Common Stock
STLN
$644M
| $379K | ﹤0.01% |
106,452
+20,605
| +24% | +$76.4K |
|
3961
Aura Biosciences
AURA
$802M
| $378K | ﹤0.01% |
69,298
+4,366
| +7% | +$25.9K |
|
3962
The Honest Company
HNST
$544M
| $378K | ﹤0.01% |
146,330
+14,876
| +11% | +$45.6K |
|
3963
Televisa
TV
$1.49B
| $377K | ﹤0.01% |
129,573
+82,256
| +174% | +$225K |
|
3964
Unisys
UIS
$206M
| $377K | ﹤0.01% |
136,550
+9,461
| +7% | +$29.6K |
|
|
TRUE
3965
DELISTED
TrueCar
TRUE
| $377K | ﹤0.01% |
166,628
+13,972
| +9% | +$30K |
|
3966
Hawthorn Bancshares
HWBK
$276M
| $376K | ﹤0.01% |
10,789
+2,073
| +24% | +$66.3K |
|
3967
New Fortress Energy
NFE
$94M
| $374K | ﹤0.01% |
328,377
+90,217
| +38% | +$133K |
|
3968
Asure Software
ASUR
$241M
| $371K | ﹤0.01% |
39,357
+3,033
| +8% | +$25.5K |
|
3969
Cricut
CRCT
$1.23B
| $371K | ﹤0.01% |
74,896
+10,116
| +16% | +$51.6K |
|
3970
Bassett Furniture
BSET
$171M
| $371K | ﹤0.01% |
22,107
+3,897
| +21% | +$61.1K |
|
3971
Concrete Pumping Holdings
BBCP
$479M
| $370K | ﹤0.01% |
55,108
+4,873
| +10% | +$32K |
|
3972
Resources Connection
RGP
$144M
| $370K | ﹤0.01% |
73,339
+5,161
| +8% | +$24.6K |
|
3973
Limoneira
LMNR
$251M
| $369K | ﹤0.01% |
29,250
+82
| +0.3% | +$1.16K |
|
3974
C&F Financial
CFFI
$288M
| $369K | ﹤0.01% |
5,086
+644
| +14% | +$44.9K |
|
3975
America's Car Mart
CRMT
$26.2M
| $368K | ﹤0.01% |
14,576
+2,339
| +19% | +$56.2K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.